Results 1 to 10 of about 4,829,888 (359)
Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies. [PDF]
Molecules, 2017 Chagas disease (CD) is a neglected disease caused by the parasite Trypanosoma cruzi, which affects underdeveloped countries. The current drugs of choice are nifurtimox and benznidazole, but both have severe adverse effects and less effectivity in chronic
Palos I +7 more
europepmc +2 more sources
Molecules, 2022 This review describes the recent Food and Drug Administration (FDA)-approved drugs (in the year 2021) containing at least one halogen atom (covalently bound).
Davide Benedetto Tiz +5 more
doaj +2 more sources
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Pharmacological ResearchOwing to the dysregulation of protein kinase activity in many diseases including cancer, this enzyme family has become one of the most important drug targets in the 21st century.
Robert Roskoski, Jr.
doaj +2 more sources
FDA no longer has to require animal testing for new drugs
Science, 2023 Description Agency can rely on animal-free alternatives before human trials Agency can rely on animal-free alternatives before human ...
M. Wadman
semanticscholar +1 more source
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
International Journal of Molecular Sciences, 2023 The development of targeted therapies has revolutionized cancer treatment, offering improved efficacy with reduced side effects compared with traditional chemotherapy.
Haesun Choi, Ji-Eun Chang
semanticscholar +1 more source
Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
Pharmaceuticals, 2023 Fluorine is characterized by high electronegativity and small atomic size, which provide this molecule with the unique property of augmenting the potency, selectivity, metabolic stability, and pharmacokinetics of drugs. Fluorine (F) substitution has been
G. Shabir +7 more
semanticscholar +1 more source
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Cancers, 2023 Simple Summary Mutations in the tumor suppressor p53 (p53) occur in ~50% of human cancers, the majority of which are missense mutations. Mutations in p53 not only impair the tumor suppressive function, but also confer missense mutant p53 (mutp53) with ...
S. Nishikawa, T. Iwakuma
semanticscholar +1 more source
Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
Journal of Neurosciences in Rural Practice, 2023 The growing prevalence of dementia makes it important for us to better understand its pathophysiology and treatment modalities, to improve the quality of life of patients and caregivers.
A. Varadharajan +8 more
semanticscholar +1 more source
FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
International Journal of Molecular Sciences, 2023 The inclusion of fluorine atoms or heterocyclic moiety into drug structures represents a recurrent motif in medicinal chemistry. The combination of these two features is constantly appearing in new molecular entities with various biological activities ...
C. Rizzo +5 more
semanticscholar +1 more source
A review of FDA approved drugs and their formulations for the treatment of breast cancer
Frontiers in Pharmacology, 2023 Breast cancer is one of the most diagnosed solid cancers globally. Extensive research has been going on for decades to meet the challenges of treating solid tumors with selective compounds.
M. Chaurasia +5 more
semanticscholar +1 more source